Brief Introduction

Micro-Tech (Nanjing) Co., Ltd. (stock ticker symbol: MTM; code: 688029) is mainly engaged in the R&D, manufacturing and sales of minimally invasive medical devices. In line with our mission of “supporting clinicians with technology and innovation,” MTM is committed to providing high-quality products and services to hospitals and clinics around the world, advancing the quality of care, improving patient outcome and maintaining low costs.

After nearly 20 years of innovation-driven development, MTM has extended its product family from non-vascular stents to three major product platforms, namely, endoscopic diagnostic instruments and consumables, tumor ablation instruments and consumables, and endoscopic optical coherence tomography (EOCT). Further, MTM has expanded our market presence from China to over 70 other countries around the world. MTM has become a leading company in the field of minimally invasive medical technology through scientific research and innovation, competitive advantage in core products and rapid growth in market share.

MTM has a stable, high-caliber, international and interdisciplinary technical team with expertise in biomedical engineering, chemical engineering, mechanical engineering, automation and computer sciences, providing a strong foundation for the company's constant innovation. MTM has won three national awards including runner-up for theNational Prize for Progress in Science and Technology, and 12 provincial and ministerial awards. Further, MTM has 36 domestic and foreign invention patents, 74 domestic Class II and Class III registration certificates, 35 U.S. FDA cleared devices, and 36 European CE certificates.

As of the end of 2018, MTM achieved an operating income of RMB 922 million and a net profit of RMB 203 million. From 2016 to 2018, the compound annual growth rate of sales revenue stood at 49.19%, much higher than other competitors in the industry .

Company Overview

Full name MICRO-TECH(NANJING)CO.,LTD
Abbreviations MTM
Code 688029
Founded 2000.5.10
Listing 2019.7.22
Domicile NANJING
Website http://www.micro-tech.com.cn
Email toni@micro-tech.com.cn
STAR Theme Biomedicine
CSRCSector Manufacturing
Has weighted voting rights structure? No

Financials

Highlights

  2018 2017 2016
Earnings Per Share 1.93 1.01 -0.38
R&D expenditure as a % of operating revenue 5.33% 5.91% 4.30%
Operating Revenue 922.11 640.67 414.31
Net Income 203.39 112.15 -26.03

Income Statement (Unit: RMB mn)

  2018 2017 2016
Operating Revenue 922.11 640.67 414.31
Operating Costs 718.25 517.85 433.76
Operating Income 225.69 131.74 -14.37
Pretax Income 234.07 131.45 -10.40
Income Tax 30.68 19.30 15.63
Net Income 203.39 112.15 -26.03

Balance Sheet(Unit: RMB mn)

  2018 2017 2016
Assets
Current Assets-Total 620.65 386.69 307.99
Non-current Assets-Total 348.57 331.63 232.52
Total Assets 969.22 718.33 540.50
Liabilities
Current Liabilities-Total 307.03 171.76 126.89
Non-current Liabilities-Total 41.83 80.38 54.68
Total Liabilities 348.85 252.14 181.57
Stockholder's Equity
Share Capital 365.47 365.47 365.47
Retained Profits 214.23 70.27 -30.93
Minority Interests 40.66 30.46 24.39
Total Owners' Equity 620.37 466.19 358.94

Cash Flow Statement (Unit: RMB mn)

  2018 2017 2016
Net Cash Flows-Operating 192.32 140.48 79.98
Net Cash Flows-Investing -26.30 -100.24 -69.45
Net Cash Flows-Financing -4.72 -13.88 34.75

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
Nanjing New weichuang Management Consulting Co., Ltd. 30.76 23.07%
Shenzhen Zhongke Merchants Venture Investment Co., Ltd. 30.18 22.63%
Huakang Limited 20.52 15.39%
Nanjing Maitai Investment Co., Ltd 4.76 3.57%
Shenzhen Huasheng Lingfeng Equity Investment(Limited Partnership) 4.50 3.37%
Green Paper Investment Limited 4.03 3.02%
Leng Derong 1.99 1.49%
Long Xiaohui 1.39 1.04%
NANJING BLUE SKY INVESTMENT CO.,LTD 1.14 0.86%
Zhang Bo 0.6 0.45%
22 Jul 2019

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.